

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Fenfluramine for treating Dravet syndrome

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

It was noted that adults with Dravet syndrome should not be excluded from consideration.

Also, comments stated that there was often difficulty in accessing treatment as an adult, and patients may currently live undiagnosed and not receiving the benefits of optimal care or appropriate treatment.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Population in scope is “people with Dravet syndrome whose seizures are inadequately controlled by current clinical management.” NICE can only make recommendations for population covered by the technology’s marketing authorisation (MA). Adults with Dravet syndrome would be considered if they are covered by the MA of fenfluramine (at the time of scoping the MA had not yet been granted).

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director (name): Nicole Elliott

Date: 20 May 2020